2.BLOUNT RE Jr, MORRIS JA, SAVAGE RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med. 1956 Jul;92(3):544-9.
3.CHANOCK R, ROIZMAN B, MYERS R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg. 1957 Nov;66(3):281-90.
4.儿童呼吸道合胞病毒感染诊断、治疗和预防专家共识[J].中华实用儿科临床杂志. 2020(04):241-250.
5.Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus--a comprehensive review. Clin Rev Allergy Immunol. 2013 Dec;45(3):331-79.
6.Coultas JA, Smyth R, Openshaw PJ. Respiratory syncytial virus (RSV): a scourge from infancy to old age. Thorax. 2019 Oct;74(10):986-993.
7.Sarah Geoghegan S, Erviti A, Caballero MT, et al. Mortality due to Respiratory Syncytial Virus. Burden and Risk Factors. Am J Respir Crit Care Med. 2017. 195(1):96-103.
8.Lu G, Gonzalez R, Guo L, et al. Large-scale seroprevalence analysis of human metapneumovirus and human respiratory syncytial virus infections in Beijing, China. Virol J. 2011 Feb 10;8:62.
9.Li Y, Johnson EK, Shi T, et al. National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study. Lancet Respir Med. 2021 Feb;9(2):175-185.
10.https://www.hjf.org/case-studies/respigam-and-synagis
11.Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol. 2008;317:103-23.
12.Births: Final data for 2020. National Vital Statistics Reports; vol 70 no 17. Hyattsville, MD: National Center for Health Statistics. 2022.
13.Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013 Aug;132(2):e341-8.
14.Rainisch G, Adhikari B, Meltzer MI, Langley G. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants. Vaccine. 2020 Jan 10;38(2):251-257.
15.Wu P, Hartert TV. Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev Anti Infect Ther. 2011. Sep; 9(9): 731–745.
16.Tian D, Battles MB, Moin SM, et al. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat Commun. 2017 Nov 30;8(1):1877.
17.Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017 May 3;9(388):eaaj1928.
18.Griffin MP, Yuan Y, Takas T, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425.
19.Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 Mar 3;386(9):837-846.
20.Arnold C. 11 clinical trials that will shape medicine in 2022. Nat Med. 2021. 27, 2062–2064
21.https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-says-key-trial-data-shows-its-rsv-vaccine-is-truly-exceptional-2022-10-13/
22.Venkatesan P. Nirsevimab: a promising therapy for RSV. Lancet Microbe. 2022 May;3(5):e335.
23.https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-06-22-23/03-RSV-McMorrow-508.pdf
【长效单克隆抗体有望为所有婴儿防护这个威胁最大的呼吸道病毒】 24.https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-04-07-00-00-2548492
相关经验推荐
- 长效染发剂和短效染发剂哪个好
- maquillage心机长效持久粉底液好用吗？
- 乙肝核心抗体阳性是什么意思
- 乙肝表面抗体阳性是什么意思
- 特稿丨“被动追赶”新冠病毒，疫苗、抗体生产商如何应对BA.4/5？
- 鼻小柱延长效果怎么样
- 嗨体打泪沟如何延长效果
- 风疹病毒抗体阳性可以怀孕吗
- 新冠疫苗抗体能维持多久 打新冠疫苗多久可以怀孕
- 打了新冠疫苗igm会变阳性吗 打了新冠疫苗怎么查抗体